Related references
Note: Only part of the references are listed.Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
D. Mahadevan et al.
EUROPEAN JOURNAL OF CANCER (2012)
Wortmannin Reduces Metastasis and Angiogenesis of Human Breast Cancer Cells via Nuclear Factor-κB-dependent Matrix Metalloproteinase-9 and Interleukin-8 Pathways
J. Li et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Multiple Myeloma
Jacob Laubach et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PI3K pathway inhibitors approach junction
David Holmes
NATURE REVIEWS DRUG DISCOVERY (2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
PI3K/p110δ is a novel therapeutic target in multiple myeloma
Hiroshi Ikeda et al.
BLOOD (2010)
Perifosine: Update on a Novel Akt Inhibitor
Joell J. Gills et al.
CURRENT ONCOLOGY REPORTS (2009)
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity
Joseph R. Garlich et al.
CANCER RESEARCH (2008)
Significance of HIF-1-active cells in angiogenesis and radioresistance
H. Harada et al.
ONCOGENE (2007)
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions
Lihua Zeng et al.
CANCER SCIENCE (2007)
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma
Hashem Younes et al.
CLINICAL CANCER RESEARCH (2007)
Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2
Weimin Li et al.
CIRCULATION RESEARCH (2007)
Hypoxia in cancer: significance and impact on clinical outcome
Peter Vaupel et al.
CANCER AND METASTASIS REVIEWS (2007)
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
Klaus Podar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Targeting signaling pathways in multiple myeloma
Cavallo Federica et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2006)
Mitogenic Signals Initiated via Interleukin-6 Receptor Complexes in Cooperation with Other Transmembrane Molecules in Myelomas
Hideaki Ishikawa et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2006)
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors
Masahiko Hayakawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BLOOD (2006)
Analysis of PTEN deletions and mutations in multiple myeloma
H Chang et al.
LEUKEMIA RESEARCH (2006)
Dissecting p53-dependent apoptosis
J. E. Chipuk et al.
CELL DEATH AND DIFFERENTIATION (2006)
Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations
S Chow et al.
CYTOMETRY PART A (2005)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma
F Pene et al.
ONCOGENE (2002)
PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects
JH Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy
LD Mayo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Biologic sequelae of interleukin-6 induced P13-K/Akt signaling in multiple myeloma
T Hideshima et al.
ONCOGENE (2001)
Expression of PTEN in PTEN-deficient multiple mgeloma cells abolishes tumor growth in vivo
NL Ge et al.
ONCOGENE (2000)
Share Paper
